JMEY-AX12

JMEY-AX12 is a pediatric drug candidate currently in the preclinical and CMC (Chemistry, Manufacturing, and Controls) stage of development by Jianmin Pharmaceutical Group. It is being developed as an expectorant, a class of medication used to help clear mucus (phlegm) from the airways, typically to treat symptoms of respiratory tract congestion or productive cough. The drug is part of Jianmin's specialized pediatric pipeline, identified by the 'JMEY' prefix, which focuses on the research and development of medications tailored for children through the Jianmin Pediatric Research Institute. As of early 2024, specific details regarding the drug's chemical composition, molecular target, and modality remain proprietary and have not been disclosed in public pipeline documentation.